ERN Rare-Liver on-demand Webinar: Sex hormonal impact in gender modification on the occur-rence of vascular liver disease

Erica Villa is a gastroenterologist and hepatologist with longstanding expertise in cirrhosis, portal hypertension, coagulation disorders, portal vein thrombosis, and hepatocellular carcinoma. Her research focuses on translational and clinical studies aimed at improving risk stratification, biomarker-based prediction, and management of patients with chronic liver disease. She has led prospective cohort studies, contributed to international collaborations, and played an active role in guideline development and scientific societies. Her work bridges hemostasis, inflammation, vascular liver disease, and liver cancer, with particular interest in the mechanisms and clinical impact of decompensation, thrombosis, and cancer progression across diverse etiologies and clinical settings.

Salvatore Fasano, MD obtained his specialization in Internal Medicine at Sapienza University of Rome, Italy. Since 2025, he has been working as a Clinical Fellow at the National Referral Centre for Vascular Liver Diseases (CRMVF), Hepatology Unit, Beaujon Hospital, Clichy, France. Current work is primarily focused on vascular liver diseases, with active involvement in national and European rare liver disease networks through FILFOIE and ERN RARE-LIVER.

Aurélie Plessier is a hepatologist at Beaujon Hospital (AP-HP), Clichy, France, and coordinator of the French Reference Centre for Vascular Liver Diseases and the FILFOIE Rare Liver Disease Network. Her work focuses on vascular liver diseases and portal hypertension She works closely with patient associations and has recently been involved in European research through the LIVES project on patient-reported outcomes (PROs). She contributes to international guidelines, including EASL and Baveno consensus recommendations.